Go back to the noodls home page
  • About us
  • Coverage
  • Services
Login

Not yet a member?Join now!|Lost password


  • Home


  • News

    • International News

    • Education

    • Environment

    • Health

    • Technology

      • Internet

    • Science

    • Social and Non-Profit

    • Local News

  • Politics 
    and Policy

    • Government and Public Administration

    • Politics

    • Local Administration

    • International Policy

  • Business 
    and Economy

    • Economy

    • Finance

      • Stock Markets

    • Jobs and Labour

    • Company News

    • Industries

      • Aerospace

      • Agriculture

      • Chemicals

        • Plastics and Rubber

      • Consumer Goods

      • Construction

      • Defense

      • Consumer Electronics

      • Energy

        • Nuclear Energy

        • Oil and Gas

        • Renewable and Alternative Energy

      • Financial Service and Investment

        • Banking

        • Insurance

      • Fishing and Aquaculture

      • Information Technology

      • Industrial and Manufacturing

        • Engineering and Heavy Industry

      • Metals

      • Mining

      • Pharmaceuticals

      • Real Estate

      • Services

        • Legal

        • Marketing and Communications

      • Telecommunications

      • Textile

      • Tobacco

      • Trade and Commerce

        • Retail

      • Transportation

        • Air Transportation

        • Maritime Transportation

        • Rail Transportation

        • Road Transportation

      • Utilities

      • Wood Industry

  • Arts 
    and Culture

    • Art

    • Book and Literature

    • Media and Entertainment

      • Cinema

      • Music

      • Radio and Television

    • Media

  • Lifestyle 
    and Leisure

    • Auto and Motors

    • Home and Garden

    • Fashion and Luxury

      • Clothing and Accessories

      • Cosmetics

      • Jewelry and Watches

    • Food and Drink

    • Travel and Tourism

    • Yacht and Sailing


  • Sports

    • Baseball

    • Basketball

    • Boxing

    • Cricket

    • Cycling

    • Football (American)

    • Football (Australian)

    • Football (Soccer)

    • Golf

    • Hockey

    • Rugby

    • Skiing and Winter Sports

    • Tennis

    • Volleyball

Cambrex Corporation

01/07/2013 | Press release

Cambrex to Exhibit at Informex USA 2013

distributed by noodls on 01/07/2013 17:23

Print Print

Sharing and Personal Tools

Please select the service you want to use:

  • Newsvine
  • Digg
  • Delicious
  • StumbleUpon
  • Technorati
  • Buzz
  • Favorites
  • Google Reader

Please use the above public link if you want to share this noodl on another website

Close

East Rutherford, NJ - January 7, 2013 - Cambrex Corporation (NYSE: CBM, "Cambrex") will be exhibiting its small molecule API products and services designed to accelerate the commercialization of finished drug products at InformexUSA 2013, February 20-22 in Anaheim, CA. In addition, Cambrex will be presenting at the Informex Exhibitor Showcase on February 19.

Cambrex will be showcasing its custom development and manufacturing capabilities including analytical development, process validation and finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, chiral compounds, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, as well as advanced pharmaceutical intermediates.

During the Informex Exhibitor Showcase, Dr. John Michnick will discuss Cambrex's high potency and ultra high potency development and manufacturing capabilities. Cambrex's high potency development center provides containment and rigorous controls to reliably and safely develop and manufacture a wide range of high potency APIs and intermediates, including oncologics and controlled substances.

Cambrex is exhibiting at booth 1523 in the Anaheim Convention Center during InformexUSA.

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.

Contact: Stephanie Harrison
               Marketing Manager
Phone:   +1 201.804.3061
Email:     stephanie.harrison@cambrex.com


Smartlinks | Cambrex Corporation | Company News | Health | Industrial and Manufacturing | Pharmaceuticals | Stocks and Security Markets | Process Industry | Healthcare Industry | Biology | Business and Corporate Announcement | Pharmaceutical Companies | New York Stock Exchange (NYSE) | Börse Frankfurt | Börse Berlin | Deutsche Börse (XETRA) | Medium and Small Cap

Back

View original format

Copyright ©2006-2013 noodls.com - VAT IT01709820995 | Privacy Policy | Terms of Use | Feedback | Contact us